Copyright © Inderes 2011 - present. All rights reserved.
Log in to receive notifications.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial calendar
    • Research
    • Articles
    • Insider transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Learn
    • Investing School
    • Q&A
    • Analysis school
  • About us
    • Our coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Herantis Pharma

1.33

 

EUR

 

-3.62 %

4,235 following

HRTIS

First North Finland

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
-3.62%
-13.64%
-12.21%
-1.48%
-13.92%
+2.7%
-29.01%
-84.02%
-86.79%

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Read more
Market cap
32.05M EUR
Turnover
16.93K EUR
P/E (adj.) (24e)
EV/EBIT (adj.) (24e)
P/B (24e)
EV/S (24e)
Dividend yield-% (24e)
Coverage
Recommendation
Accumulate
Target price
Updated
23.08.2024
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 23.08.2024

Latest extensive report

Released: 25.06.2024

Revenue and EBIT-%
10106.76.73.33.3003.9K21212222232324e24e25e25e26e26e

Revenue K

EBIT-% (adj.)

EPS and dividend
00-0.4-0.4-0.8-0.8-1.2-1.221212222232324e24e25e25e26e26e

EPS (adj.)

Dividend %

Financial calendar
6.3.
2025

Annual report '24

24.4.
2025

General meeting '25

21.8.
2025

Interim report Q2'25

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types
Herantis H2’24 preview: Phase I clinical trial to be completed this year
Analyst Comment19 hours ago by
Antti Siltanen

Herantis H2’24 preview: Phase I clinical trial to be completed this year

The company initiated a Phase Ib clinical trial in Parkinson's disease with HER-096 during the reporting period.

Herantis Pharma
Press release2/24/2025, 8:15 AM

Herantis Pharma: Invitation to Full Year 2024 report webinar on March 6, 2025

Herantis Pharma
Herantis Pharma, Webcast, Q4'24
Webcast3/6/2025, 12:30 PM

Herantis Pharma, Webcast, Q4'24

Herantis Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release2/18/2025, 2:00 PM

Herantis Pharma: Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act

Herantis Pharma
Regulatory press release2/17/2025, 7:20 AM

Herantis Pharma Plc: 1,311,363 new shares registered with the trade register

Herantis Pharma
Regulatory press release2/10/2025, 6:35 AM

Herantis Pharma Plc: 2,622,721 new shares registered with the trade register

Herantis Pharma
Analyst Comment2/7/2025, 6:39 AM by
Antti Luiro

Herantis Pharma collected 5.2 MEUR in gross assets from the directed share issue as expected

The funds raised in the issue will strengthen the company's financial position until the topline data of the HER-096 phase 1b trial are released in Q3'25. The company commented that it will continue its partnership discussions and preparations for the phase 2 trial.

Herantis Pharma
Regulatory press release2/6/2025, 6:30 PM

Inside information: Herantis Pharma Plc successfully completes a directed share issue raising EUR 5.2 million

Herantis Pharma
Analyst Comment1/28/2025, 9:25 AM by
Antti Luiro

Herantis Pharma Phase 1b clinical trial is progressing

Herantis reported in a press release that the first patient with Parkinson's disease received a test dose of the drug in the second part of the Phase 1b clinical trial.

Herantis Pharma
Press release1/28/2025, 7:00 AM

Herantis Pharma: encouraging pharmacokinetic data and first subject with Parkinson’s disease dosed in the Phase 1b trial

Herantis Pharma
Regulatory press release1/20/2025, 11:15 AM

Herantis Pharma Oyj: Managers' Transactions – Aki Prihti

Herantis Pharma
Regulatory press release1/20/2025, 11:00 AM

Herantis Pharma Oyj: Managers' Transactions – Aki Prihti

Herantis Pharma
Drug development investment: Value creation through M&As and licensing agreements
Article12/19/2024, 11:07 AM by
Antti Siltanen

Drug development investment: Value creation through M&As and licensing agreements

The fourth part of our series of articles focusing on investing in Life Science companies deals with value creation in drug development companies through M&As and licensing agreements.

Faron PharmaceuticalsHerantis PharmaOrionModulight
Regulatory press release12/12/2024, 2:00 PM

Herantis Pharma’s financial calendar and annual general meeting for 2025

Herantis Pharma
Regulatory press release12/10/2024, 4:30 PM

Proposals of the Shareholders' Nomination Committee to Herantis Pharma Plc's Annual General Meeting 2025

Herantis Pharma
Herantis Pharma as an Investment | Life Science Night Dec. 2, 2024
Video12/3/2024, 12:50 PM

Herantis Pharma as an Investment | Life Science Night Dec. 2, 2024

Antti Vuolanto, CEO, talks about biotechnology company Herantis Pharma as an investment.

Herantis Pharma
Analyst Comment12/3/2024, 6:52 AM

Life Science Night available on inderesTV

Aiforia TechnologiesHerantis PharmaFaron Pharmaceuticals
Life Science Companies as Investments | Life Science Night Dec. 2, 2024
Video12/2/2024, 2:00 PM

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia TechnologiesBBS-Bioactive Bone SubstitutesBioretecBiohitFaron PharmaceuticalsModulightNexstimOrionBittiumDetection TechnologyOptomedRevenio GroupNightingale HealthHerantis PharmaNanoform Finland
Life Science Night | December 2, 2024
Webcast12/2/2024, 2:00 PM

Life Science Night | December 2, 2024

Welcome to follow Life Science Night on Monday, December 2 at 4:00 pm EET on inderesTV.

Aiforia TechnologiesHerantis PharmaFaron Pharmaceuticals
Regulation of drug development
Analyst Comment12/3/2024, 10:21 AM by
Antti Siltanen

Regulation of drug development

The third part in our series of articles on investing in Life Science companies deals with regulatory issues. Regulatory processes are demanding and time-consuming, and failure to comply can be disastrous for a drug development company.

Faron PharmaceuticalsHerantis PharmaOrionMendusModulight
Forum discussions
Rahoitus varmistettu 1b faasin loppuun saattamiseen. Sisäpiiritieto: Herantis Pharma Oyj toteuttaa onnistuneesti suunnatun osakeannin ja kerää sen tuloksena 5,2 miljoonaa euroa | Kauppalehti
2/6/2025, 6:46 PM
by Alamäki
15
Mielestäni tämä Krog 3 vastaus on hyvä ja analyyttinen —> potentiaalia on ja hyvät partnerit. Latest News on Herantis Pharma and Parkinson’s Herantis Pharma, a Finland-based clinical-stage biotech company, is actively working on a potential disease-modifying therapy for Parkinson...
3/2/2025, 9:35 AM
by Oxymoron 007
8
Yksi kilpailija taas putoaa pois Parkinsonin lääkekisasta. https://www.fiercebiotech.com/biotech/inhibikase-therapeutics-hits-pause-parkinsons-program-it-prioritises-lung-drug Tuo lääkekandidaatti, Risvodetinib, vaikuttaisi olevan Abl inhibiittori, joka taas näyttäisi vaikuttavan...
1/30/2025, 1:43 PM
by jerej
8
Tällainen uutine tuli vastaan: https://www.fiercebiotech.com/biotech/biogen-axes-asset-73b-buyout-plus-alzehimers-and-parkinsons-prospects In early Parkinson’s, Biogen stopped the development of the Ionis-partnered BIIB094. The antisense oligonucleotide targets LRRK2, reflecting ...
2/16/2025, 8:16 PM
by jerej
5
Omistajalista päivittynyt sivuille. Tuosta näkee nyt ketkä ovat olleet rahoittamassa edellistä antia helmikuussa. omistaja muutos Skandinaviska Enskilda Banken Ab (publ) Helsingin Sivukonttori +1647633 Joensuun Kauppa Ja Kone Oy +113636 Sijoitusrahasto Säästöpankki Pienyhtiöt +75757...
yesterday
by jerej
4
Tässä on Luiron kommentit Herantiksen annista. Inderes Herantis Pharma keräsi odotetusti 5,2 MEUR:n bruttovarat suunnatulla... Annissa kerätyillä varoilla vahvistetaan yhtiön rahoitustilannetta käynnissä olevan HER-096 vaiheen 1b tutkimuksen loppuluentaan Q3’25 saakka. Yhtiö kommentoi...
2/7/2025, 7:47 AM
by Sijoittaja-alokas
4
Tässä on Antin etkokommentit, kun Herantis julkaisee H2-raporttinsa torstaina 6.3. Herantis julkistaa H2-raporttinsa torstaina 6.3. Klo 14:30 alkava webcast on katsottavissa täällä. Yhtiö aloitti vaiheen Ib kliinisen tutkimuksen Parkinsonin taudissa HER-096 tutkimuslääkkeellä raportointika...
20 hours ago
by Sijoittaja-alokas
3
Read more on our forum
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial calendar
    • Research
    • Articles
    • Insider transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Learn
    • Investing School
    • Q&A
    • Analysis school
  • About us
    • Our coverage
    • Team

Privacy preferences

Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.